Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | BLM | P54132 | 2/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237823 | 1.00 | GABRR1 (0.35) | GABRR1EPHX1SLC1A2SLC1A1CYP2D6 | |
| SCHEMBL2266700 | 1.00 | GABRR1 (0.35) | GABRR1EPHX1SLC1A2SLC1A1CYP2D6 | |
| SCHEMBL8191588 | 0.89 | EPHX1 (0.40) | EPHX1BLMTSHRRAB9AMEN1 | |
| SCHEMBL895753 | 0.89 | EPHX1 (0.40) | EPHX1BLMTSHRRAB9AMEN1 | |
| SCHEMBL11199858 | 0.89 | EPHX1 (0.40) | EPHX1BLMTSHRRAB9AMEN1 | |
| SCHEMBL7857943 | 0.89 | PEPD (0.36) | GABRR1EPHX1BLMMEN1KMT2A | |
| SCHEMBL11199862 | 0.89 | EPHX1 (0.40) | EPHX1BLMTSHRRAB9AMEN1 | |
| SCHEMBL4744040 | 0.83 | — | — | |
| SCHEMBL22546037 | 0.83 | — | — | |
| SCHEMBL4812482 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111111475-B | Preparation method of graphene oxide modified triptycenyl polyamide separation membrane | 南京工业大学 | 2022-03-22 | — | — | CN | claimed |
| EP-3323500-B1 | MANUFACTURING METHOD FOR TRIPTYCENE POLYMER CARRIER FILM | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2021-01-27 | — | — | EP | claimed |
| US-10799836-B2 | Preparation method for triptyl polymer separation membrane | NANJING TECH UNIVERSITY (CN) | 2020-10-13 | — | — | US | claimed |
| CN-111111475-A | Preparation method of graphene oxide modified triptycenyl polyamide separation membrane | 南京工业大学 | 2020-05-08 | — | — | CN | claimed |
| US-20180236408-A1 | A PREPARATION METHOD FOR TRIPTYL POLYMER SEPARATION MEMBRANE | NANJING TECH UNIVERSITY (CN) | 2018-08-23 | — | — | US | claimed |
| EP-3323500-A1 | MANUFACTURING METHOD FOR TRIPTYCENE POLYMER CARRIER FILM | Nanjing Tech University (CN) | 2018-05-23 | — | — | EP | claimed |
| CN-111111475-B | Preparation method of graphene oxide modified triptycenyl polyamide separation membrane | 南京工业大学 | 2022-03-22 | — | — | CN | disclosed |
| EP-3323500-B1 | MANUFACTURING METHOD FOR TRIPTYCENE POLYMER CARRIER FILM | NANJING UNIVERSITY OF TECHNOLOGY (CN) | 2021-01-27 | — | — | EP | disclosed |
| US-10799836-B2 | Preparation method for triptyl polymer separation membrane | NANJING TECH UNIVERSITY (CN) | 2020-10-13 | — | — | US | disclosed |
| CN-111111475-A | Preparation method of graphene oxide modified triptycenyl polyamide separation membrane | 南京工业大学 | 2020-05-08 | — | — | CN | disclosed |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | Sunovion Pharamaceuticals Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-2861596-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharamaceuticals Inc. | 2018-09-13 | — | — | US | disclosed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5532372-A | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| US-5502075-A | Leukotriene-B4 derivatives, process for their production and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| WO-1995004732-A1 | OLIGOPEPTIDE ANTIRETROVIRAL AGENTS | SYNPHAR LABORATORIES, INC. (CA) | 1995-02-16 | — | — | WO | disclosed |
| WO-1992013838-A1 | OLIGOPEPTIDE ANTIRETROVIRAL AGENTS | SYNPHAR LABORATORIES, INC. (CA) | 1992-08-20 | — | — | WO | disclosed |
| EP-0464846-A1 | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
| US-5023335-A | Antitumor agents | ASTA PHARMA AKTIENGESELLSCHAFT | 1991-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | GABRR1 314/4885EPHX1 1105/4885SLC1A2 517/4885 |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | PDE10A, PDE2A, PDE3A | GABRR1 435/4885EPHX1 682/4885SLC1A2 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.